| Jun 26 | Jun 25 | Jun 24 | Jun 23 | Jun 22 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | AU$ 0.00 | AU$ 136.00K | AU$ 17.00K | AU$ 405.90K | AU$ 295.81K |
| Gross Profit | AU$ -117.71K | AU$ 136.00K | AU$ -25.98K | AU$ -3.00M | AU$ 88.75K |
| Operating Income | AU$ -11.21M | AU$ -11.20M | AU$ -10.81M | AU$ -9.68M | AU$ -7.59M |
| EBITDA | AU$ -11.10M | AU$ -11.10M | AU$ -10.63M | AU$ -10.37M | AU$ -7.87M |
| Net Income | AU$ -6.92M | AU$ -7.51M | AU$ -8.75M | AU$ -10.18M | AU$ -8.62M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | AU$ 14.35M | AU$ 20.88M | AU$ 12.71M | AU$ 5.18M | AU$ 6.07M |
| Total Assets | AU$ 15.01M | AU$ 21.60M | AU$ 13.28M | AU$ 5.47M | AU$ 9.21M |
| Total Debt | AU$ 0.00 | AU$ 0.00 | AU$ 0.00 | AU$ 144.80K | AU$ 144.80K |
| Net Debt | AU$ -14.35M | AU$ -20.88M | AU$ -12.71M | AU$ -5.18M | AU$ -5.93M |
| Total Liabilities | AU$ 857.45K | AU$ 1.52M | AU$ 2.06M | AU$ 1.69M | AU$ 1.60M |
| Stockholders' Equity | AU$ 14.15M | AU$ 20.08M | AU$ 11.23M | AU$ 3.78M | AU$ 7.62M |
| Cash Flow | |||||
| Free Cash Flow | AU$ -6.95M | AU$ -7.34M | AU$ -7.04M | AU$ -6.40M | AU$ -6.83M |
| Operating Cash Flow | AU$ -6.91M | AU$ -6.93M | AU$ -6.91M | AU$ -6.40M | AU$ -6.27M |
| Investing Cash Flow | AU$ -40.48K | AU$ -432.11K | AU$ -179.34K | AU$ 95.42K | AU$ -566.00K |
| Financing Cash Flow | AU$ 488.69K | AU$ 15.52M | AU$ 14.61M | AU$ 5.41M | AU$ 6.19M |
Arovella Therapeutics Limited (DE:E4NA)
FRANKFURT:E4NA
